Europe Artificial Skin Market

Europe Artificial Skin Market Size (2022 to 2027)

The size of the artificial skin market in the European region is expected to grow at a CAGR of 5.58% from 2022 to 2027.

The Y-O-Y growth in acute and chronic wounds is one of the key drivers driving the European artificial skin market. As consumers become more aware of the different skin care alternatives, artificial skin becomes more popular. Auto rejection is impossible because artificial skin lacks immunogenic cells like dendritic cells. Increasing burn injuries, chronic and acute wounds such as diabetic foot ulcers, increased R&D efforts for the development of new products, technological advancements such as sprays for treating burn injuries using a patient's cells, and a rise in health care expenditure are expected to drive the artificial skin market in Europe. In addition, increased awareness of various skin treatment techniques has increased the demand for artificial skin in Europe.

Ulcers burden the healthcare system since they are challenging to diagnose and treat. Sedentary lifestyles, poor eating habits, and chronic diseases like diabetes and obesity often cause chronic wounds. The demand for quick wound healing has increased as diabetes and obese persons have increased. As a result, artificial skin that regenerates is expected to be in high demand in the coming years. These factors will drive the European artificial skin market during the forecast period.

High prices associated with artificial skin implants, strict regulations on the launch of new goods, and poor awareness in low-income economies are projected to hamper the European artificial skin market throughout the projection period. Furthermore, low- and middle-income countries suffer from a lack of healthcare infrastructure and medical services. As a result, European market expansion is likely to be difficult over the projection period. In addition, they are expensive for many individuals because of their high cost. Compared to synthetic skin transplants, biological skin grafts may be less expensive. The availability of experienced plastic surgeons is another significant challenge to the European artificial skin market.

This report on the European artificial skin market has been segmented and sub-segmented into the following categories.

By Product Type:

• Permanent

• Temporary

• Composite

By Replacement area:

• Dermal

• Epidermal

• Composed

By Material:

• Natural

• Synthetic

• Both

By Application:

• Acute wounds

• Chronic wounds

• Others

By End User:

• Hospitals

• Burn care Centers

• Others

By Country:

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe

In 2022, the European regional market accounted for the second-largest share of the global market. Auto rejection is not observed because artificial skin lacks immunogenic cells such as dendritic cells. The artificial skin market has seen substantial growth because of an increase in the frequency of vehicle accidents, burns, and trauma-related incidents. The key driving force in Europe has been the rising developments in healthcare-based technologies such as tissue engineering technology and biotechnology.

The UK artificial skin market is expected to lead the European market throughout the projected period. By regularly investing in research and development, manufacturers look for new ways to produce new products. As new vendors enter the market, established suppliers' profit margins are shrinking due to rising competition. To maintain their market positions, incumbent suppliers are encouraged to develop new goods by raising their R&D spending.

Following the United Kingdom, the German artificial skin market holds the second-largest European Artificial Skin market during the forecast period. As car accidents, burns, and trauma-related incidents have increased, the artificial skin market has grown dramatically. The market in Germany is predicted to grow rapidly during the forecast period, owing to increased research and development efforts, increased government measures to improve health care, and a surge in critical companies' focus on developing or reinforcing their presence in the region.

KEY MARKET PLAYERS:

Companies playing a prominent role in the European artificial skin market profiled in this report are AVITA Medical, Eucare Pharmaceuticals (P) Ltd., MiMedx, Aroa Biosurgery Limited, Integra LifeSciences, Mallinckrodt Pharmaceuticals, Medskin Suwelack, Misonix, and Organogenesis, Inc.